<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Earlier cancer detection, wider reimbursement and emerging-market access boost demand, while oral therapies, antimetabolites, ADCs, telehealth and online pharmacies create opportunities.Dublin, Aug. 28, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6266801/cytotoxic-drugs-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=fnl5jx&amp;utm_campaign=2340437+-+Cytotoxic+Drugs+Market+Report+Now+Available+%e2%80%94+Forecasts+Market+Growth+from+%2416.21B+(2026)+to+%2421.06B+by+2031%2c+Profiling+Pfizer%2c+Roche%2c+Novartis%2c+AstraZeneca%2c+Sanofi%2c+and+15+Other+Key+Players&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Cytotoxic Drugs - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Cytotoxic Drugs - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. Cytotoxic Drugs Market to Reach USD 21.06 Billion by 2031 as Cancer Treatment Demand Expands The global cytotoxic drugs market is estimated to reach USD 16.21 billion in 2026, up from USD 15.38 billion in 2025. The market is projected to grow at a compound annual growth rate of 5.37% from 2026 to 2031, reaching USD 21.06 billion by the end of the forecast period. Rising cancer incidence, earlier diagnosis, expanded chemotherapy reimbursement and growing demand in emerging economies are expected to support sustained market growth. Rising Cancer Incidence Strengthens Cytotoxic Drug Demand The increasing global cancer burden remains a primary driver of the cytotoxic drugs market. Newly diagnosed cancer cases in the United States surpassed 2.04 million in 2025, creating a substantial treatment population for chemotherapy and combination regimens. Aging populations, improved imaging technologies and AI-enabled screening are also helping healthcare providers identify malignancies earlier, when cytotoxic therapies continue to play an important role in treatment. Population-wide screening programs in emerging markets are further increasing the number of diagnosed patients and supporting demand for cost-effective chemotherapy. Higher treatment volumes, longer therapy durations and broader access to oncology services are expected to reinforce baseline market growth through 2031. Expanded Reimbursement Improves Chemotherapy Access Reimbursement reforms are reducing financial barriers to cancer treatment. Medicare's introduction of a USD 2,000 annual cap on patient out-of-pocket drug costs in 2025 is expected to improve access to multi-agent chemotherapy protocols and support treatment adherence. Private insurers are increasingly adopting similar measures, while China has expanded its national medical insurance list to include recently approved cytotoxic drugs. European healthcare systems also continue to provide comprehensive oncology coverage. These developments are widening access to chemotherapy, supporting the use of combination treatments and encouraging the adoption of newly approved cytotoxic formulations. Pipeline progress in next-generation formulations and increasing demand across low- and middle-income countries provide additional growth opportunities. Adverse Effects Remain a Key Market Restraint Despite improving access, the adverse-effect profile of cytotoxic therapies continues to affect dosage adherence and treatment completion. Discontinuation rates in colorectal cancer treatment have ranged from 27% to 53%, highlighting the impact of toxicity on real-world outcomes. Supply disruptions involving cornerstone agents, including the cisplatin shortages reported in 2023, have also increased reliance on alternatives and exposed vulnerabilities in chemotherapy supply chains. Supportive care, pharmacist-led monitoring and digital adherence programs can help manage these challenges. However, toxicity concerns and the pharmaceutical industry's increasing investment in targeted therapies and immuno-oncology may moderate the expansion of conventional cytotoxic treatments. Oral Cytotoxic Drugs Record Accelerated Growth Parenteral cytotoxic drugs held 68.87% of the market in 2025, supported by clinician preference for controlled dosing in acute, induction and combination regimens. Oral cytotoxic drugs are forecast to expand at a faster 8.79% CAGR through 2031 as oncology care increasingly moves toward home-based administration. Advances in bioavailability and sustained-release formulations are improving the role of oral therapies in long-term treatment plans. Telehealth monitoring, electronic prescribing and online pharmacy distribution are also helping patients follow dosing schedules and manage side effects. Injectable therapies will remain essential when rapid cytoreduction is required, but patient demand for convenient oral options is shifting market momentum. Alkylating Agents Lead While Antimetabolites Gain Momentum Alkylating agents accounted for 30.10% of the cytotoxic drugs market in 2025 due to their established use across hematologic malignancies and solid tumors. Antimetabolites are expected to post the fastest growth among major drug categories, advancing at a 7.02% CAGR through 2031. Their combination potential and evolving toxicity profiles are supporting wider clinical use. Drug development programs are also incorporating cytotoxic payloads into antibody-drug conjugates, including topoisomerase inhibitors and plant alkaloid derivatives. These strategies are extending the commercial potential of established compounds while improving delivery to antigen-expressing tumors. North America Leads as Asia-Pacific Posts Fastest Growth North America represented 42.15% of global revenue in 2025, supported by broad insurance coverage, strong clinical trial activity and investment in oral formulations and antibody-drug conjugates. Reimbursement reforms in the United States are expected to widen treatment access and improve adherence. Asia-Pacific is projected to grow at a robust 10.07% CAGR, driven by expanding manufacturing capacity, regulatory momentum and increasing oncology investment. China approved 228 drugs in 2024, with antineoplastic medicines accounting for 37% of the total. India, Japan and South Korea are also advancing local manufacturing, bioconjugate research and cancer treatment innovation. Europe continues to benefit from harmonized regulatory procedures and broad public healthcare access, although pricing scrutiny remains high. The Middle East, Africa and South America are generating new opportunities as oncology infrastructure, pooled procurement programs and multilateral health initiatives expand chemotherapy availability. Together, these trends are expected to support the continued development of the global cytotoxic drugs market through 2031. Key Topics Covered: 1 Introduction 1.1 Study Assumptions &amp; Market Definition 1.2 Scope of the Study 2 Research Methodology 3 Executive Summary 4 Market Landscape 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Cancer Incidence &amp; Earlier Diagnosis 4.2.2 Expanding Reimbursement For Chemotherapy Regimens 4.2.3 Pipeline Approvals Of Next-Gen Cytotoxic Formulations 4.2.4 Surging Demand Across Low- And Middle-Income Countries 4.2.5 AI-Driven Drug-Repurposing Accelerating Cytotoxic Combos 4.2.6 ADC (Antibody-Drug Conjugate) Payload Demand For Cytotoxics 4.3 Market Restraints 4.3.1 Severe Adverse-Effect Profile Limits Dosage Adherence 4.3.2 High Cost Of HPAPI Containment &amp; Compliance (USP-800, EMA) 4.3.3 Shift Of R&amp;D Budgets Toward Targeted &amp; Immuno-Oncology Drugs 4.3.4 Environmental Regulations On Cytotoxic Effluent Disposal 4.4 Supply-Chain Analysis 4.5 Porter's Five Forces 4.5.1 Threat of New Entrants 4.5.2 Bargaining Power of Buyers 4.5.3 Bargaining Power of Suppliers 4.5.4 Threat of Substitutes 4.5.5 Intensity of Competitive Rivalry 5 Market Size &amp; Growth Forecasts (Value, USD) 5.1 By Route of Administration 5.1.1 Parenteral 5.1.2 Oral 5.2 By Drug Type 5.2.1 Alkylating Agents 5.2.2 Antitumor Antibiotics 5.2.3 Antimetabolites 5.2.4 Plant Alkaloids 5.2.5 Topoisomerase Inhibitors 5.2.6 Others 5.3 By Application 5.3.1 Breast Cancer 5.3.2 Prostate Cancer 5.3.3 Lung Cancer 5.3.4 Pancreatic Cancer 5.3.5 Colorectal Cancer 5.3.6 Others 5.4 By Distribution Channel 5.4.1 Hospital Pharmacies 5.4.2 Retail Pharmacies &amp; Drug Stores 5.4.3 Online Pharmacies 5.4.4 Other Distribution Channels 5.5 Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 Asia-Pacific 5.5.3.1 China 5.5.3.2 Japan 5.5.3.3 India 5.5.3.4 South Korea 5.5.3.5 Australia 5.5.3.6 Rest of Asia-Pacific 5.5.4 Middle East and Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East and Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America 6 Competitive Landscape 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments) 6.3.1 Baxter International Inc. 6.3.2 Cipla Ltd 6.3.3 Eli Lilly and Company 6.3.4 Fresenius Kabi AG 6.3.5 Johnson &amp; Johnson 6.3.6 Viatris Inc 6.3.7 Novartis AG 6.3.8 Pfizer Inc. 6.3.9 Sun Pharmaceutical Industries 6.3.10 Teva Pharmaceutical Industries 6.3.11 Sanofi SA 6.3.12 Roche Holding AG 6.3.13 AstraZeneca PLC 6.3.14 Merck &amp; Co., Inc. 6.3.15 Amgen Inc. 6.3.16 Lonza Group (HPAPI CDMO) 6.3.17 Dr. Reddy's Laboratories 6.3.18 Hikma Pharmaceuticals 6.3.19 Intas Pharmaceuticals 6.3.20 Alvogen 7 Market Opportunities &amp; Future Outlook 7.1 White-space &amp; unmet-need assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6266801/cytotoxic-drugs-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=fnl5jx&amp;utm_campaign=2340437+-+Cytotoxic+Drugs+Market+Report+Now+Available+%e2%80%94+Forecasts+Market+Growth+from+%2416.21B+(2026)+to+%2421.06B+by+2031%2c+Profiling+Pfizer%2c+Roche%2c+Novartis%2c+AstraZeneca%2c+Sanofi%2c+and+15+Other+Key+Players&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/1yd2ue</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MmQ5YjhiMmQtZDU3Zi00MDZhLTlmYmUtYTg0NGY3NTRkYWU2LTEwMjY3MzctMjAyNi0wOC0yOC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Cytotoxic Drugs Market Report Now Available — Forecasts Market Growth from $16.21B (2026) to $21.06B by 2031, Profiling Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and 15 Other Key Players

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn